Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 1.00 |
| ▸ | GBA1 | P04062 | 6/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.53 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.53 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7637770 | 1.00 | FUCA1 (1.00) | FUCA1GBA1ALDH1A1SIGMAR1S1PR1 | |
| SCHEMBL1860555 | 1.00 | FUCA1 (1.00) | FUCA1GBA1ALDH1A1SIGMAR1S1PR1 | |
| SCHEMBL15599205 | 0.96 | FUCA1 (0.92) | FUCA1GBA1ALDH1A1SIGMAR1S1PR1 | |
| SCHEMBL15599027 | 0.96 | FUCA1 (0.92) | FUCA1GBA1ALDH1A1SIGMAR1S1PR1 | |
| SCHEMBL15599028 | 0.96 | FUCA1 (0.92) | FUCA1GBA1ALDH1A1SIGMAR1S1PR1 | |
| SCHEMBL17181666 | 0.96 | FUCA1 (0.92) | FUCA1GBA1ALDH1A1SIGMAR1S1PR1 | |
| SCHEMBL5155562 | 0.92 | FUCA1 (0.85) | FUCA1GBA1ALDH1A1SIGMAR1S1PR1 | |
| SCHEMBL71063 | 0.92 | FUCA1 (0.85) | FUCA1GBA1ALDH1A1SIGMAR1S1PR1 | |
| SCHEMBL20017877 | 0.92 | FUCA1 (0.85) | FUCA1GBA1ALDH1A1SIGMAR1S1PR1 | |
| SCHEMBL562632 | 0.92 | FUCA1 (0.85) | FUCA1GBA1ALDH1A1SIGMAR1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197471-A1 | Treatment of degenerative cartilage conditions in a mammal with Glycosidasc Inhibitors | OPTIMER PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070197471-A1 | Treatment of degenerative cartilage conditions in a mammal with Glycosidasc Inhibitors | OPTIMER PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-6462193-B1 | ADDING 3-AZIDO-2-HYDROXYPROPANALDEHYDE WITH DIHYDROXYACETONE PHOSPHATE USING AN ALDOLASE, HYDROLYZING THE INTERMEDIATE WITH ACID PHOSPHATASE, ISOMERIZING USING AN ISOMERASE, CYCLIZING USING REDUCTIVE AMINATION TO PRODUCE TETRAHYDROXYAZEPINE | THE SCRIPPS RESEARCH INSTITUTE | 2002-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197471-A1 | Treatment of degenerative cartilage conditions in a mammal with Glycosidasc Inhibitors | MMP1, MMP13, MMP3 | FUCA1 6/4885GBA1 51/4885ALDH1A1 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.